<div id="readability-page-1">Procept Biorobotics Corp. (NASDAQ:PRCT) is one of the most promising mid-cap healthcare stocks under $50. On December 12, UBS analyst Danielle Antalffy initiated coverage with a bullish rating on Procept Biorobotics Corp. (NASDAQ:PRCT). She rated the stock as a Buy and estimated a target price of $62. This leads to an upside potential of over […]</div>

PRCT

<p>瑞銀分析師 Danielle Antalffy 對 Procept Biorobotics Corp.（納斯達克代碼：PRCT）啓動了覆蓋，給予 “買入” 評級，目標價為 62 美元，顯示出顯著的上漲潛力</p>

樂觀的增長預測使分析師對 PROCEPT BioRobotics（PRCT）充滿信心